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Lack of Prognostic Value of Type D Personality for Mortality in a Large
Sample of Heart Failure Patients
JAMES C. COYNE, PHD, TINY JAARSMA, RN, PHD, MARIE-LOUISE LUTTIK, PHD, ERIC VAN SONDEREN, PHD,
DIRK J. VAN VELDHUISEN, PHD, MD, AND ROBBERT SANDERMAN, PHD
Background: Type D personality has been proposed as a prognostic indicator for mortality in cardiovascular disease. Most research
examining this construct originates from one research group, and it is critical that the predictive value of Type D personality for adverse
outcomes is independently cross-validated. This study examined its prognostic value in heart failure, relative to B-type natriuretic
peptide (BNP) and depressive symptoms. Methods: We studied 706 patients with complete BNP, depressive symptom, and Type D
personality and mortality data from 958 patients with heart failure enrolled after hospitalization for a multisite study of a disease
management program. Multivariable models were adjusted for BNP and depression. Results: At 18 months, there were 192 deaths
(27.2%). No evidence was found for a prognostic value of Type D personality in the unadjusted model (hazard ratio [HR] = 0.893,
95% conﬁdence interval [CI] = 0.582Y1.370). In contrast, BNP was signiﬁcantly predictive of mortality (HR = 1.588, 95% CI =
1.391Y1.812), whereas depression was not (HR = 1.011, 95% CI = 0.998Y1.024). Type D was also not predictive in covariate-adjusted
models (HR = 0.779, 95% CI = 0.489Y1.242). Similar results were obtained when analyzing Type D as the interaction between
continuous z scores of its two components, negative affectivity and social inhibition (p = .144). Conclusions: In the largest study to
date, Type D does not predict mortality. Future research should construe Type D as the interaction of continuous negative affectivity
and social inhibition z scores, rather than as a typology, and consider analyses replacing negative affectivity with depression.
Key words: Type D personality, heart failure, survival, B-type natriuretic peptide, depression.
BNP = B-type natriuretic peptide; HF = heart failure; CES-D =
Center for Epidemiologic Studies Depression; NYHA = New York
Heart Association.
INTRODUCTION
S tarting with an often-cited Lancet article (1), Type D per-sonality, which has been deﬁned as the tendency to expe-
rience negative emotions and to inhibit self-expression in social
interaction, has been proposed as a prognostic indicator for
mortality in cardiovascular disease independent of biologic
factors, including disease severity. However, the original Lancet
study excluded deaths in the ﬁrst 5 years, with an observation
period of 6 to 12 years. After exclusion of these 93 patients,
only 21 deaths remained to be explained, too few events to justify
the multivariate regression analyses, which were thus overﬁtted,
with a high risk of spurious ﬁndings (2). A series of subsequent
studies mostly had small samples, inconsistent scoring of the
Type D measure, varying start and length of follow-up periods,
and overﬁtted regression equations, with six (3), eight (4), twelve
(5) and four (6) deaths, respectively, being explained. These
studies tended to have fewer events being explained than the
number of covariates considered for entering into multivariate
analyses. A later study reported on 47 deaths in a mean obser-
vation period of 30 months among patients with heart failure
(HF) and found a signiﬁcant effect for Type D (odds ratio = 2.16,
95% conﬁdence interval = 1.05Y4.43, p = .04) that did not persist
when confounds were controlled (7). More recently, Type D was
not found to predict 123 deaths among 641 HF patients in bi-
variate or multivariate analyses (8). It is noteworthy that, thus
far, all studies relating Type D personality to mortality were
conducted by the same investigator group, with the exception
of one small study in which there were null ﬁndings, but only
11 deaths to explain (9).
Proposals have nonetheless been made for routine screening
of patients with cardiovascular disease for Type D personality
(10) and the use of Type D for stratiﬁcation purposes (11). The
clinical utility of this variable remains to be independently
established. We undertook an evaluation of Type D personality
as a predictor of mortality among HF patients, taking advantage
of a large-scale clinical trial with almost as many events (death)
as all previous Type D mortality studies combined. Assess-
ments of patients were available with a biomarker, B-type natri-
uretic peptide (BNP), which has emerged as a reliable indicator
of the severity of HF (12,13), and with depressive symptoms,
an established prognostic indicator for clinical outcomes in
coronary heart disease and HF (14), was also available.
MATERIALS AND METHODS
Study Design
This report draws on data from the previously reported Coordinating study
evaluating Outcomes of Advising and Counselling in Heart failure (COACH)
trial in the Netherlands (15,16), a multicenter, randomized controlled trial with
blinded end point evaluation designed to evaluate the effects of disease man-
agement, that is, advising and counseling of HF patients. The COACH trial
revealed no signiﬁcant treatment effects on mortality (16). Patients were assessed
for Type D personality at baseline (during hospitalization) and followed for
mortality for 18 months thereafter.
Study Population
Patients were recruited between October 2002 and February 2005 while
hospitalized for symptomatic HF (New York Heart Association [NYHA]
IIYIV). Patients were required to be at least 18 years old and have evidence of
structural underlying heart disease. Patients with impaired and preserved left
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ventricular ejection fraction were included. Major exclusion criteria were con-
current inclusion in another study or HF clinic, inability to complete ques-
tionnaires, invasive procedures or cardiac surgery performed within the last
6 months or planned within the next 3 months, ongoing evaluation for heart
transplantation, and inability or unwillingness to give informed consent. Of the
958 patients enrolled in the trial, 706 had complete data for BNP, depressive
symptoms, and Type D personality, and so, they were included in the present
analyses.
Once informed consent was signed, baseline data collection started, and
afterward, patients were randomized into one of three groups: basic support,
intensive support, or control. The study complied with the Declaration of
Helsinki, and the protocol was reviewed and approved by a central appointed
ethics committee.
Data Collection
Data on mortality were collected from medical records. All reported deaths
were reviewed by an independent clinical end point committee who deﬁned the
date and cause of death. The time of death from point of randomization was
entered into Cox proportional hazards regression models.
Type D personality was assessed at baseline using the Type D scale (14-item
version [DS14]), consisting of two seven-item subscales, that is, negative af-
fectivity and social inhibition (17). As customary, patients were deﬁned as
having Type D personality when they scored 10 or higher on both subscales.
The DS14 is generally construed to measure two temporally stable personality
traits, as indicated by good test-retest reliability, and to be independent from
changes in mood (17).
Depressive symptoms were assessed at baseline with the Center for Epi-
demiologic Studies Depression (CES-D) Scale (18,19), a 20-item well-validated
measure that is commonly used with cardiac patients. The scores range from
0 to 60, and a validated cut point of 16 or higher is typically used to distinguish
between low and high levels of depressive symptoms.
BNP measurement in this sample is described elsewhere (20). Basically,
BNP plasma levels were determined using a Triage ﬂuorescence immunoassay
kit (Biosite Inc., San Diego, CA) within 4 hours of blood collection on the
day of hospital discharge or 1 day before hospital discharge. For simplifying
interpretation, BNP values were divided by 1000. Patients with available BNP
levels did not differ in demographic or clinical characteristics, and the rates
of Type D personality were not signiﬁcantly different ( p = .56) between
patients with available BNP levels (n = 721, 13%) and patients who did not
have a BNP measurement (n = 237, 12%).
Statistical Analysis
Descriptive sample statistics for baseline characteristics of the whole sample
were calculated, as well as the prevalence of Type D personality and the rela-
tionship between Type D classiﬁcation and key variables. Bivariate associations
of Type D classiﬁcation and mortality were calculated.
A Cox proportional hazards regression model was constructed for Type D
personality. BNP and depressive symptoms were entered as the ﬁrst block in an
equation predicting mortality, with the entry of Type D in the second block
testing the hypothesis that Type D classiﬁcation had signiﬁcant added prog-
nostic value. Other potential control variables were considered but had to
meet the requirement of not only being related to both Type D personality
and mortality but also as potentially preceding or determining both Type D
personality and mortality. We thus did not evaluate potential mediators of
Type D on mortality as confounders (21,22).
Taxometric analyses (23) suggest that Type D is better represented as
a dimensional construct rather than a categorical construct. Moreover, there is
a long-standing consensus among psychometricians and personality theorists
TABLE 1. Baseline Characteristics in Relation to Type D Personality
Total Sample (n = 706) Type D (n = 95, 13%) NonYType D (n = 611, 87%) p
Demographic variables
Age, M (SD), y 70.7 (11.5) 69.3 (12.3) 70.9 (11.3) .203
Female sex, % 38.2 42.1 37.6 .405
Clinical variables
LVEF, M (SD), % 33.8 (14.3) 34.7 (15.2) 33.7 (14.2) .533
History of AF, % 33.4 34.7 33.2 .771
NYHA (at discharge), %
II 49.4 37.6 51.2
IIIYIV 50.6 62.4 48.8 .015
Ischemic etiology, % 43.2 45.3 42.9 .663
Q1 comorbidity, % 78.6 76.8 78.9 .651
Prior HF admission, % 33.4 34.7 33.2 .771
BNP, M (SD) 0.674 (0.72) 0.659 (0.61) 0.676 (0.74) .697
Medication at discharge, %
ACE/ARB 84.0 80.0 84.6 .254
Diuretics 96.5 96.8 96.4 .828
A-Blockers 65.2 60.0 66.0 .257
Lipid-lowering drugs 37.7 35.8 38.0 .683
Antidepressants 6.1 13.7 4.9 .001
Negative affectivity, M (SD) 6.4 (6.0) 15.8 (4.3) 4.9 (4.7)
Social inhibition, M (SD) 7.9 (7.1) 16.8 (5.0) 6.5 (6.3)
Depression
CES-D, M (SD) 15.4 (10.7) 25.9 (10.7) 13.8 (9.7) G.001
Q16, % 39.9 76.8 34.2 G.001
M = mean; SD = standard deviation; LVEF = left ventricular ejection fraction; AF = atrial ﬁbrillation; NYHA = New York Heart Association; HF = heart failure;
BNP = B-type natriuretic peptide; ACE/ARB = angiotensin-converting enzyme/angiotensin receptor blocker; CES-D = Center for Epidemiologic Studies Depression.
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that the practice of dichotomizing two continuous variables and constructing a
typology for a resulting 2  2 matrix of high-low groups is variously unnec-
essary, highly problematic, and prone to spurious associations and therefore
should be avoided (24Y27). We therefore also analyzed the arguably more
appropriate prediction of mortality from z scores for the components negative
affectivity and social inhibition and their interaction term.
RESULTS
Baseline Characteristics
The present analyses included 706 patients who had BNP
assessments and CES-D scores and who completed all 14
questions of the DS14. Analyses of differences between the
706 patients and the larger sample of 958 participants in the
COACH trial from which they were drawn revealed only that
patients included in the study were lower in prescription of
antidepressants, (6.1% versus 9.9%), t test, p G .04. In total,
95 patients (13%) in the present sample were identiﬁed as
having a Type D personality. Baseline characteristics of the
study sample are provided in Table 1. Mean age of the study
sample was 70.7 years, and 38.2% of them were women.
At hospital discharge, 49.4% of the patients were classiﬁed
as having NYHA functional Class II disease, and 50.6% were
classiﬁed as having NYHA III or IV disease. A total of 43.2%
had ischemic HF with a history of a myocardial infarction.
Type D classiﬁcation was not associated with baseline char-
acteristics with the exception of NYHA classiﬁcation and use
of antidepressants, and a strong association with depressive
symptoms, whether measured dichotomously or with CES-D
continuous scores. Pearson correlations between continuous
CES-D scores and the two continuous components of Type D,
negative affectivity and social inhibition, were 0.62 (n = 706,
p G .001) and 0.34 (p G .001), respectively.
Table 2 provides baseline characteristics for both survival
states. Survival was related to age, all clinical variables in-
cluding angiotensin-converting enzyme/angiotensin receptor
blocker medication, with the exception of percent left ventricu-
lar ejection fraction and other medication. The only variable that
was signiﬁcantly related to both Type D and survival was
NYHA. Because we did not construe this variable as a deter-
minant of Type D, there was no need to control for this vari-
able in the Cox proportional hazards regression model.
Relationship Between Type D and Mortality
All cause mortality rate for the study sample was 27.1% (n =
192). A Cox proportional hazards regression model relating
Type D classiﬁcation to mortality was not signiﬁcant. Figure 1
depicts survival curves for Type D versus nonYType D. Al-
though not signiﬁcant at 18 months, the advantage of Type D
personality for survival would have to be reversed substantially
for a disadvantage of Type D personality to emerge at some
point beyond our 18-month observation period.
TABLE 2. Baseline Characteristics in Relation to Survival
Total Sample (n = 706) Dead (n = 192, 27%) Alive (n = 514, 73%) p
Demographic variables
Age, M (SD), y 70.7 (11.5) 74.4 (10.0) 69.3 (11.7) G.001
Female sex, % 38.2 33.9 39.9 .142
Clinical variables
LVEF, M (SD), % 33.8 (14.3) 33.3 (14.5) 34.0 (14.3) .622
History of AF, % 33.4 45.8 28.8 G.001
NYHA (at discharge), %
II 49.4 38.9 53.3
IIIYIV 50.6 61.1 46.7 .001
Ischemic etiology, % 43.2 51.0 40.3 .010
Q1 comorbidity, % 78.6 87.0 75.5 .001
Prior HF admission, % 33.4 45.8 28.8 G.001
BNP, M (SD) 0.674 (0.72) 0.952 (0.91) 0.570 (0.60) G.001
Medication at discharge, %
ACE/ARB 84.0 76.6 86.8 .001
Diuretics 96.5 97.9 95.9 .200
A-Blockers 65.2 59.9 67.1 .073
Lipid-lowering drugs 37.7 37.5 37.7 .953
Antidepressants 6.1 6.8 5.8 .644
Negative affectivity, M (SD) 6.4 (6.0) 6.2 (5.7) 6.4 (6.0) .772
Social inhibition, M (SD) 7.9 (7.1) 7.8 (6.8) 7.9 (7.2) .952
Type D personality, % 13.5 12.5 13.8 .649
Depression, M (SD) 15.4 (10.7) 16.4 (10.3) 15.0 (10.8) .114
CES-D Q16, % 39.9 44.3 38.3 .151
M = mean; SD = standard deviation; LVEF = left ventricular ejection fraction; AF = atrial ﬁbrillation; NYHA = New York Heart Association; HF = heart failure;
BNP = B-type natriuretic peptide; ACE/ARB = angiotensin-converting enzyme/angiotensin receptor blocker; CES-D = Center for Epidemiologic Studies Depression.
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As seen in Table 3, BNP levels and CES-D scores were
entered as a ﬁrst block in a Cox proportional hazards regression
model, and the overall block proved a signiﬁcant predictor
of mortality, but this was because of the contribution of BNP
levels, with the contribution of CES-D scores not signiﬁcant
(Model 1). In Model 2, the dichotomous variable Type D was
added. This did not improve the prediction of mortality.
Table 4 again starts with a model with BNP levels and CES-
D scores (Model 1). This time, in Model 2, the two components
of Type D, negative affection and social inhibition (z scores),
were entered together with their interaction. The interaction
term was not signiﬁcant in improving the prediction of mor-
tality, again indicating that Type D did not contribute to the
prediction of mortality when using continuous scores. To inter-
pret the main effects of negative affection and social inhibition,
the interaction term was removed, resulting in the ﬁnal Model 3.
BNP level seemed to be the best predictor of mortality. De-
pression also predicted mortality but to a limited degree.
DISCUSSION
No evidence was found for the prognostic value of Type
D personality for all-cause mortality in HF patients, either in
unadjusted Cox proportional hazards regression models or ad-
ditive or independent of BNP in multivariate Cox proportional
hazards regression models or as an effect modiﬁer for BNP.
These results held in analyses treating Type D as a dichotomous
typology as well as in more appropriate analyses examining
Type D for the interaction of negative affectivity and social
inhibition. These results stand in contrast to what was obtained
for the prognostic value of BNP. Suggestions that Type D
personality be routinely assessed in HF patients or be used for
stratiﬁcation are premature, at least for the prediction of mor-
tality in HF patients.
Type D classiﬁcation was most strongly related to depressive
symptoms and to treatment with antidepressants, a likely proxy
for clinical depression. Although the developers of the Type D
measure assert that Type D is independent of mood (17), there
is a notable overlap in the content of measures assessing de-
pressive symptoms and the two components of Type D, nega-
tive affectivity and social inhibition. Consistent ﬁndings that
the components of Type D are related to depressive symptoms
have led to suggestions that Type D and depressive symptoms
are both facets of negative affectivity and that any prediction of
clinically signiﬁcant outcomes by Type D independent of de-
pressive symptoms might, as has been suggested previously, be
considered to be an artifact of creation of a Type D personality
typology from variables that are essentially continuous (23,28).
In the present sample, the correlation between CES-D and one
component of Type D, negative affectivity, approached the
maximum predicted from the respective reliabilities of the two
scales.
Initial Cox proportional hazards regression model in our
study were constructed consistent with all past studies testing
the prognostic value of Type D for mortality, namely, with Type
D treated as a typology with patients high in both negative
affectivity and social inhibition being contrasted with the other
three quadrants in a high-low, 2 2 cross tabulation of negative
affectivity and social inhibition. Next, we obtained the same
null results in our treatment of Type D for the interaction be-
tween continuous negative affectivity and social inhibition z
scores. However, our second analytic strategy is more defen-
sible and appropriate, given not only conclusions of taxometric
analyses that indicate that Type D is best construed in contin-
uous, dimensional terms rather than a typology but also a
consensus that has emerged for more than 30 years in the
psychometric and personality theory literature that typologies
created from high-low, 2  2 crossings of continuous dimen-
sional variables are inappropriate and prone to spurious ﬁnd-
ings (24Y27). We ﬁnd these arguments compelling and suggest
that future Type D personality research adopt our analytic
Figure 1. Survival for Type D.
TABLE 3. Cox Proportional Hazards Regression Model of Survival Status
With Type D Dichotomized
95% CI for
Exp (B)
B SE Wald df p HR Lower Upper
Model 1
BNP 0.46 0.07 46.07 1 G.001 1.59 1.39 1.81
Depression 0.01 0.01 2.30 1 .130 1.01 0.997 1.023
Model 2
BNP 0.46 0.07 45.12 1 G.001 1.58 1.38 1.81
Depression 0.01 0.01 3.38 1 .066 1.01 0.999 1.028
Type D j0.25 0.24 1.10 1 .294 0.78 0.49 1.24
Continuous score for depression was used.
SE = standard error; df = degrees of freedom; HR = hazard ratio; CI = conﬁ-
dence interval; Exp = exponentiation of; BNP = B-type natriuretic peptide.
J. C. COYNE et al.
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strategy of focusing on the interaction of negative affectivity
and social inhibition or explain why it is not being adopted.
In our present sample, depressive symptoms were not a sig-
niﬁcant predictor of mortality, although the association was in
the expected direction. However, the present sample was lim-
ited to patients for whom both BNP and assessment of Type D
personality were available (n = 706). These patients were drawn
from a larger sample (N = 938) in which depressive symptoms
were modestly associated with morality (HR = 1.169, p = .02)
(20). The larger literature is mixed concerning the prediction of
mortality in HF from depressive symptoms, particularly when
mortality is examined separately, rather than simply treated as
one aspect of a composite end point. A recent review of studies
of the association of depressive symptoms and mortality in HF
reported null ﬁndings for inpatient samples, but most studies
of outpatients found an association (29). The present sample
was recruited and assessed during an inpatient stay.
The strong association between one component of Type D,
negative affectivity, and both depressive symptoms and use of
antidepressants raises the possibility that, in addition to pre-
serving the components of Type D as continuous variables, fu-
ture research should examine whether depressive symptoms
could be substituted for negative affectivity without any sub-
stantial loss in predictive power with respect to clinical variables.
The association between depressive symptoms and cardiovas-
cular outcomes is stronger and based on a more substantial
literature than is the case for Type D. Routine screening for
depression in cardiovascular patients has already been recom-
mended by a number of professional organizations (30), even if
the beneﬁts of screening for cardiovascular outcomes are yet to
be established (31). Furthermore, it is unlikely that calls for
screening for Type D (11) will lead to the DS14 supplanting
measures of depression. NonYmental health clinicians are no-
tably averse to introducing and sustaining routine psychological
screening (32) and report that even brief depression screening
measures, such as the nine-item Patient Health Questionnaire,
are too long (33,34). If, however, it could be shown that a brief,
seven-item measure of social inhibition added substantially to
the predictive ability of depressive symptoms, perhaps screening
for social inhibition could be added to screening for depression.
Null ﬁndings from one large study might be contradicted
by subsequent studies, but we note important limitations in the
small studies that have been cited in support of a prognostic
value for Type D personality with respect to mortality. Claims
for the prognostic value of Type D may ﬁt the pattern of other
psychosocial variables purportedly predicting mortality, for in-
stance, ﬁghting spirit in the prediction of mortality of cancer
patients (35). Speciﬁcally, initial claims are based on under-
powered studies but could not be validated in subsequent large-
scale studies with appropriate control of biomedical variables.
Reasons for the rise, persistence, and ultimate fall of such hy-
potheses are undoubtedly varied. They likely include early
positive results, capitalizing on chance or multivariate analyses
where bivariate associations are not signiﬁcant, and methodo-
logical limitations of the small studies, as well as publication
bias (36,37). Supporting the hypothesis of a publication bias,
we note that previous studies with positive ﬁndings have had
4 to 21 deaths to be explained, too few to justify the multivariate
analyses that were used. Moreover, such a small number of
deaths being explained in the individual studies could not be
expected to generate a consistent pattern of positive ﬁndings
unless an exceptionally large and unprecedented effect of per-
sonality on mortality was present.
This study had the advantage of an adequate sample size
and being one of the ﬁrst studies with regard to mortality con-
ducted outside the original Type D investigator group. Some of
the patients included in this study were from the same clinical
settings providing patients to earlier studies, and the remaining
TABLE 4. Cox Proportional Hazards Regression Model of Survival Status With Type D as Interaction Between Negative Affectivity and Social Inhibition
95% CI for Exp (B )
B SE Wald df p HR Lower Upper
Model 1
BNP 0.46 0.07 46.07 1 G.001 1.59 1.39 1.81
Depression 0.01 0.01 2.30 1 .130 1.01 0.997 1.023
Model 2
BNP 0.46 0.07 43.27 1 G.001 1.58 1.38 1.80
Depression 0.02 0.01 5.01 1 .025 1.02 1.00 1.04
Negative affectivity (z score) j0.10 0.10 1.12 1 .289 0.90 0.74 1.09
Social inhibition (z score) j0.03 0.08 0.15 1 .695 0.97 0.84 1.13
Negative affectivity by social inhibition j0.10 0.07 2.13 1 .144 0.90 0.79 1.04
Model 3
BNP 0.46 0.07 43.38 1 G.001 1.58 1.38 1.81
Depression 0.02 0.01 4.92 1 .027 1.02 1.00 1.04
Negative affectivity (z score) j0.14 0.10 2.01 1 .156 0.87 0.72 1.05
Social inhibition (z score) j0.03 0.08 0.19 1 .659 0.97 0.83 1.12
Continuous score for depression was used.
SE = standard error; df = degrees of freedom; HR = hazard ratio; CI = conﬁdence interval; Exp = exponentiation of; BNP = B-type natriuretic peptide.
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patients were drawn from the same larger, cultural and medical
system context, the Netherlands. However, the prevalence of
Type D personality (13%) was lower than in previous studies.
It was nonetheless consistent across recruitment sites, including
those involved in past studies of Type D. It is quite possible that
recruitment to a disease management program such as COACH
attracts a lower proportion of patients with Type D personality.
This study had the limitation of being a secondary analysis
of a clinical trial not having been designed expressly to test the
prognostic value of Type D. Its follow-up period was limited
to 18 months, and we cannot exclude the possibility that effects
of Type D personality on mortality are not apparent until later.
However, emergence of a disadvantage of Type D for sur-
vival would require a substantial reversal of trends apparent up
to 18 months. We are unaware of any plausible mechanism by
which Type D should come into play after 18 months and affect
in a clinically signiﬁcant way the survival of the patients who
survive until then.
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